bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic
and orphan diseases, today announced the acquisition of Precision Genome
Engineering, Inc., or Pregenen, a privately held biotechnology company
headquartered in Seattle, Washington.
for bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company investment picks